BioVie cuts offering 72% to 16M shares at $1.56, adds warrants; net proceeds drop to $22.7M

Filed August 14, 2026 · Compared to S-1/A Aug 6, 2026 · ~2 min read

Key Changes

• high

  Offering restructured: size reduced from 56.4M to 16.0M shares (72% cut), assumed price raised from $1.33 to $1.56, and Common Warrants added one-for-one with each share. Estimated net proceeds fell from $70.0M to $22.7M (68% reduction).

  Offering Terms view on EDGAR →
• high

  Best-efforts offering with no minimum proceeds requirement. Company may raise substantially less than $22.7M and investors will not receive refunds. Nasdaq may delist the stock if it determines the offering does not qualify as a 'public offering' under Rule 5635.

  Risk Factors: Offering Structure verify on EDGAR →
• high

  On August 12, 2026, warrant holders exercised 528,539 common warrants and 380,000 pre-funded warrants (cashless), issuing 908,510 shares. This event occurred between filings and materially affects dilution calculations.

  Dilution verify on EDGAR →